All Biotech companies at once!

Project information panel

03K – Oral off-patent oncology drugs for kids

There is an urgent need for appropriate oral formulations of anticancer drugs for the treatment of paediatric malignancies in children. The goal of the O3K consortium is to develop oral liquid formulations of Cyclophosphamide and Temozolomide, important chemotherapeutics which have been identified in the list of paediatric needs by EMEA (EMEA/197972/2007). Both off-patent drugs are widely used orally for the treatment of childhood cancer. However, the currently available tablets (Cyclophosphamide) and capsules (Temozolomide) are not suitable for use in a paediatric setting, particularly in infants and young children, as it is often impractical for them to be swallowed. This is a major health concern since these children do not readily have direct and safe access to these curative drugs. The NODS« technology represents an innovative oral drug delivery system for drinkable products for children. Drug entrapment in NODS« particles provides gastroprotection, stabilization, chemical protection of labile compounds and taste masking. O3K will conduct the pharmaceutical, clinical and pharmacological studies required for the development of these oral liquid formulations. Upon completion of the project, a dossier containing data required for application for a Paediatric Use Marketing Authorisation (PUMA) will be filed for both products. The EMEA Scientific Advice is already ongoing. O3K will provide access to curative drugs for all children with cancer, improving compliance, ensuring safety for both patient and environment and allowing the development of essential ambulatory treatments. In accordance with ICH guidelines, the development of these agents will lead to improved quality and safety of paediatric drug formulations. The O3K project involves 9 partners (including 5 institutions and 3 SMEs providing expertise in clinical and pharmacological research relating to paediatric oncology along with 1 parents organisation) from three European member states (UK, It and Fr)

  •  2008-09-01  2011-08-31
  • FP7-HEALTH / HEALTH-2007-4.2-1 / FP7-HEALTH-2007-B
  • Overall Cost: 6.84 M.Eur
  •   > Keocyt
  • Other project partners
  • Adapting off-patent medicines to the specific needs of paediatric populations 
  • Medicine, Health; Social Aspects 
  • FP7 Data provision: © European Union; Source: CORDIS, Cordis | This page is not provided by the European Commission 

 Pharmaceutical   research   cancer   pharma   Development   drug   Oncology   drugs   Health   europe   technology   products   chemical   formulation   stabilization   clinical   treatment   delivery   lab   capsules   quality   therapeutic   therapeutics   compounds   search   Patient   innovative   Environment   Marketing   Gen   product   data   drug delivery   safety   application   patent   liver   oral   compound   gas   develop   protection   scientific   lead   Skin   Pharmacological   expertise   Expert   studies   improve   gent   needs   Latin   Agent   system   IDI   MPO   project   anticancer drugs   drug delivery system   ABI   European   chemo   Pharmaceutical   research   cancer   pharma   Development   drug   Oncology   drugs   Health   europe   Pharmaceutical   research   cancer   pharma   Development   drug   Oncology   drugs   Health   europe   technology   products   chemical   formulation   stabilization   clinical   treatment   delivery   lab   capsules   quality   therapeutic   therapeutics   compounds   search   Patient   innovative   Environment   Marketing   Gen   product   data   drug delivery   safety   application   patent   liver   oral   compound   gas   develop   protection   scientific   lead   Skin   Pharmacological   expertise   Expert   studies   improve   gent   needs   Latin   Agent   system   IDI   MPO   project   anticancer drugs   drug delivery system   ABI   European   chemo 

comments powered by Disqus

Report an error:

Did you noticed an error? Please report here...


Top Countries

 DE 933
 UK 761
 NL 663
 IT 616
 FR 516
 BE 315
 ES 306
 CH 305
 SE 237
 AT 179

Top Business Area

 RED 3030
 WHI 1096
 SEL 643
 GRE 489
 CON 311
 ANA 285
 DNA 158
 INF 144
 JOB 36

EU-Projects Champions

 Acreo 41
 Johnson 37
 DSM 32
 Biotec 30
 Tecna 28

Top Legal Types

 LTD 2381
 PLC 1071